Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
Annu Navani 55 Director Yue Alexander Wu, Ph.D. (1)(2)(3) 62 Director (1) Member of the Audit Committee. (2) Member of the Compensation Committee. (3) Member of the Semnur Nominating and Corporate Governance Committee. (4) Commercialization and Transaction Committee Executive Officers Jaisim Shah. Mr. Shah serves as Semnur’s Chief Executive Officer and President and a member of the Board. He has served as Semnur’s President, Chief Executive Officer and a board member since its inception in 2013. Mr. Shah has more than 25 years of global biopharma experience, including over 15 years in senior management leading business development, commercial operations, investor relations, marketing and medical affairs. Mr. Shah also previously served as Scilex’s President and Chief Executive Officer from March 2019 to August 2024, and a board member of Scilex from March 2019 to September 2025, and as a member of the board of directors of Scilex Pharma since November 2016. Prior to his time at Semnur, Mr.
This record is keyed to SEC CIK 0002033328 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 42 institutional-holder rows on these vehicles, under 19 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.